Literature DB >> 3319496

Cephalosporins in gram-positive infections.

J Symonds1, A M Geddes.   

Abstract

Infections caused by Gram-positive bacteria are an important and common cause of morbidity and mortality. Staphylococci and streptococci are the most frequent infecting organisms in skin and soft tissue infections, pneumonia, bone and joint infections, and endocarditis. Anaerobic Gram-positive bacteria such as Clostridia spp. cause infections that can rapidly produce tissue necrosis and death. The cephalosporins are indicated for the treatment of infections caused by Gram-positive bacteria in certain circumstances. These include selected patients with endocarditis, osteomyelitis, septic arthritis and cellulitis. They are also used as alternatives to the penicillins in penicillin-allergic patients and for 'mixed' infections caused by Gram-positive and Gram-negative organisms. This article discusses the indications for the cephalosporin group of antibiotics in patients suffering from infections caused by Gram-positive bacteria.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3319496     DOI: 10.2165/00003495-198700342-00010

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  112 in total

1.  Cephalosporin therapy of staphylococcal infections in adults. A review of the literature and a report of 501 treated patients.

Authors:  I M Smith
Journal:  Postgrad Med J       Date:  1971-02       Impact factor: 2.401

2.  Ceftizoxime in moderate-to-severe infections.

Authors:  E S Johnson; L G Smith
Journal:  J Antimicrob Chemother       Date:  1982-11       Impact factor: 5.790

3.  Pharmacokinetics and clinical studies with cefadroxil in paediatrics.

Authors:  A Windorfer; P Bauer
Journal:  J Antimicrob Chemother       Date:  1982-09       Impact factor: 5.790

Review 4.  Microbiological investigation of cephalosporins.

Authors:  J M Hamilton-Miller
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 5.  Cephalosporin antibiotics as applied in surgery of bones and joints.

Authors:  H C Neu
Journal:  Clin Orthop Relat Res       Date:  1984-11       Impact factor: 4.176

6.  Comparative study of the serum bactericidal activity of cefoperazone alone and in combination with amikacin or mezlocillin against gram-negative bacilli and Staphylococcus aureus.

Authors:  H Lagast; J Klastersky; H Standiford; A Viollier
Journal:  Infection       Date:  1984 May-Jun       Impact factor: 3.553

7.  Clinical efficacy of cefotaxime in serious infections.

Authors:  P H Karakusis; J M Feczko; L J Goodman; D M Hanlon; A A Harris; S Levin; G M Trenholme
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

8.  Ceftriaxone for the treatment of serious infections.

Authors:  R W Steele; R W Bradsher
Journal:  Am J Dis Child       Date:  1983-11

9.  Treatment of infective endocarditis due to viridans streptococci, This statement was prepared by the ad hoc subcommittee on Treatment of Bacterial endocarditis of the American Heart Association Council on Cardiovascular Disease in the Young.

Authors:  A L Bisno; W E Dismukes; D T Durack; E L Kaplan; A W Karchmer; D Kaye; M A Sande; J P Sanford; W R Wilson
Journal:  Circulation       Date:  1981-03       Impact factor: 29.690

10.  Cephalexin: preliminary in vitro studies of a new orally administered cephalosporin and report of a case of endocarditis cured with cephalexin.

Authors:  R J Zabransky; M A Gardner; J E Geraci
Journal:  Mayo Clin Proc       Date:  1969-12       Impact factor: 7.616

View more
  3 in total

Review 1.  Cephalosporin utilisation review and evaluation.

Authors:  G M Misan; C Dollman; D R Shaw; N Burgess
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

Review 2.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

Review 3.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.